A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimer’s Disease (ADEPT-4)
Lay Description
Category
- Child Health
- Nervous System
- IRB Number
- STUDY00000895
- NCT Number
- NCT # not yet entered
Eligibility
- Eligible Ages
- Eligible Genders
- Accepts Healthy Volunteers
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Rose Barajas
210-450-8219
barajasr@uthscsa.edu
Floyd Jones
210-450-3158
jonesfa@uthscsa.edu
Amy Saklad
210-567-8229
saklada@uthscsa.edu
Principal Investigator
Antonio Lucio Teixeira Junior